Informed Decision Making for Patients with Advanced Pancreatic Cancer Considering Chemotherapy: Development and Evaluation of a Clinical Decision Aid for Patients

Pancreatic cancer is the fourth leading cause of cancer death in Canada. Significant advancements in chemotherapy for advanced pancreatic cancer have resulted in the need for a quantitative comparison between these treatments on a relative scale. Therefore, a systematic review and Bayesian network meta-analysis of randomized clinical trials was conducted using gemcitabine, the standard treatment, as the reference comparator. Based on results from the network meta-analysis, in which optimal treatments were identified and side effects of each treatment evaluated, an Internet-based patient decision aid was developed in order to present the benefits and risks of each therapy option: (1) Best supportive care (2) gemcitabine (3) FOLFIRINOX. The objective of the decision aid was to guide patients through the decision-making process based on their individual preferences and values. The decision aid was deemed to be acceptable and feasible based on results from a pilot study conducted at The Ottawa Hospital Cancer Centre.

Grantor dc:publisher

Université d'Ottawa / University of Ottawa

Year dc:date

2013

Author dc:creator

• Gresham, Gillian

Contributors dc:contributor

• Wells, George

• Advanced Pancreatic Cancer
• Chemotherapy
• Systematic Review
• Network meta-analysis
• Decision Aid
• Gemcitabine
• FOLFIRINOX
• Acceptability
• Feasibility

Language dc:language

en

Identifier

http://dx.doi.org/10.20381/ruor-6694

OAI identifier oai:identifier

oai:ruor.uottawa.ca:10393/24395